Fumaric Acid

Fumaric Acid

SCHEMBL466968

N#Cc1ccc(C(=O)CC2CCN(CC3CC3)CC2)cc1.O=C(O)/C=C/C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
DRD2 known ✓ P14416 2/20 0.60
HTR2A known ✓ P28223 2/20 0.60
HTR2C known ✓ P28335 2/20 0.60
HTR2B known ✓ P41595 2/20 0.60
SIGMAR1 Q99720 4/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL466969 1.00 SIGMAR1 (0.86) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL7357328 0.93 SIGMAR1 (1.00) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL7364658 0.77 SIGMAR1 (0.76) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL7358604 0.76 SIGMAR1 (0.74) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL7363419 0.76 SIGMAR1 (0.74) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL7358803 0.76 SIGMAR1 (1.00) SIGMAR1DRD2HTR2AHTR2CHTR2B
Bromide SCHEMBL467156 0.75 SIGMAR1 (1.00) SIGMAR1DRD2HTR2AHTR2CHTR2B
SCHEMBL16578740 0.71 SIGMAR1 (0.62) SIGMAR1
SCHEMBL8430052 0.70 SIGMAR1 (0.61) SIGMAR1
SCHEMBL10787275 0.70 SIGMAR1 (0.61) SIGMAR1DRD2HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2600863-B1 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA ESTEVE LABOR DR (ES) 2018-03-28 EP disclosed
EP-2646025-B1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN ESTEVE LABOR DR (ES) 2017-03-15 EP disclosed
EP-2531191-B1 Sigma ligands for use in the prevention and/or treatment of postoperative pain ESTEVE LABOR DR (ES) 2016-03-30 EP disclosed
EP-2571501-B1 SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY ESTEVE LABOR DR (ES) 2016-03-02 EP disclosed
EP-2460519-A1 Use of sigma ligands in bone cancer pain Laboratorios Del. Dr. Esteve, S.A. (ES) 2012-06-06 EP disclosed
EP-2415471-A1 Use of sigma ligands in opioid-induced hyperalgesia Laboratorios Del. Dr. Esteve, S.A. (ES) 2012-02-08 EP disclosed
EP-2388005-A1 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-11-23 EP disclosed
EP-2353598-A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-08-10 EP disclosed